Evidence map›Paper›PMID 32043185›Full record

ArticleDiabetologia2020

Metabolic alterations in immune cells associate with progression to type 1 diabetes.

Partho Sen, Alex M Dickens, María Asunción López-Bascón, Tuomas Lindeman, Esko Kemppainen, Santosh Lamichhane, Tuukka Rönkkö, Jorma Ilonen, Jorma Toppari, Riitta Veijola and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetologia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Genome-scale models in human metabologenomics.Nature reviews. Genetics · 2025
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Pharmacometabolomics of sulfonylureas in patients with type 2 diabetes: a cross-sectional study.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2024
    Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 3 countries.

Partho SenTurku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520, Turku, Finland. partho.sen@utu.fi.
Alex M DickensTurku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520, Turku, Finland.
María Asunción López-BascónDepartment of Analytical Chemistry, University of Córdoba, Córdoba, Spain.
Tuomas LindemanTurku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520, Turku, Finland.
Esko KemppainenTurku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520, Turku, Finland.
Santosh LamichhaneTurku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520, Turku, Finland.
Tuukka RönkköTurku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520, Turku, Finland.
Jorma IlonenImmunogenetics Laboratory, Institute of Biomedicine, University of Turku, Turku, Finland.
Jorma ToppariDepartment of Pediatrics and Adolescent Medicine, Turku University Hospital, Turku, Finland.
Riitta VeijolaDepartment of Pediatrics, PEDEGO Research Unit, Medical Research Centre, University of Oulu, Oulu, Finland.
Heikki HyötyFaculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
Tuulia HyötyläinenDepartment of Chemistry, Örebro University, Örebro, Sweden.
Mikael KnipChildren's Hospital, University of Helsinki and Helsinki University Hospital, 00290, Helsinki, Finland. mikael.knip@helsinki.fi.
Matej OrešičTurku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520, Turku, Finland. matej.oresic@utu.fi.
Åbo Akademi University · FIUniversity of Turku · FIÖrebro University · SEHelsinki University Hospital · FIOulu University Hospital · FIPirkanmaa Hospital District · FITurku Centre for Computer Science · FITurku University Hospital · FIUniversity of Córdoba · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisPrevious metabolomics studies suggest that type 1 diabetes is preceded by specific metabolic disturbances. The aim of this study was to investigate whether distinct metabolic patterns occur in peripheral blood mononuclear cells (PBMCs) of children who later develop pancreatic beta cell autoimmunity or overt type 1 diabetes.

methodsIn a longitudinal cohort setting, PBMC metabolomic analysis was applied in children who (1) progressed to type 1 diabetes (PT1D, n = 34), (2) seroconverted to ≥1 islet autoantibody without progressing to type 1 diabetes (P1Ab, n = 27) or (3) remained autoantibody negative during follow-up (CTRL, n = 10).

resultsDuring the first year of life, levels of most lipids and polar metabolites were lower in the PT1D and P1Ab groups compared with the CTRL group. Pathway over-representation analysis suggested alanine, aspartate, glutamate, glycerophospholipid and sphingolipid metabolism were over-represented in PT1D. Genome-scale metabolic models of PBMCs during type 1 diabetes progression were developed by using publicly available transcriptomics data and constrained with metabolomics data from our study. Metabolic modelling confirmed altered ceramide pathways, known to play an important role in immune regulation, as specifically associated with type 1 diabetes progression. CONCLUSIONS/

interpretationOur data suggest that systemic dysregulation of lipid metabolism, as observed in plasma, may impact the metabolism and function of immune cells during progression to overt type 1 diabetes. DATA AVAILABILITY: The GEMs for PBMCs have been submitted to BioModels (www.ebi.ac.uk/biomodels/), under accession number MODEL1905270001. The metabolomics datasets and the clinical metadata generated in this study were submitted to MetaboLights (https://www.ebi.ac.uk/metabolights/), under accession number MTBLS1015.

Indexed as

AdultAgedAged, 80 and overAutoantibodiesAutoimmunityDiabetes Mellitus, Type 1Disease ProgressionFemaleGenotypeHumansIslets of LangerhansLeukocytes, MononuclearLipid MetabolismLongitudinal StudiesMaleMiddle AgedAutoantibodiesSphingolipidsBirth cohortCeramidesGenome-scale metabolic modellingLipidomicsMetabolomicsPeripheral blood mononuclear cellsSphingolipid metabolismType 1 diabetes

Identifiers

PMID32043185
PMCPMC7145788
OpenAlexW3006496439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.